A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis
Atopic Dermatitis (AD): Phase 3 double-blinded study, 8 week study with 44 week long-term safety period with guaranteed study medicine. Topical cream. Male and females ≥ 2 Years to < 12 Years with AD Atopic Dermatitis (AD), also known as eczema, is an inflammatory skin condition that can reoccur repeatedly. AD often causes itching and burning, skin flaking, and red bumps that can crust and open up. The purpose of this study is to find out of the study medicine, ruxolitinib cream, can help with the treatment of AD.
Participants in this research study will need to return to the research site for up to 17 visits over 61 weeks. At this visits, participants will be asked to complete questionnaires, undergo blood draws, complete photography, and undergo physical and skin exams.
Up to $850.00
AD covering between 3% and 20% body surface
Willing to follow all study guidelines
Positive for Hepatitis B, Hepatitis C, or HIV
Previous treatment with JAK inhibitors